ArticleFrontiers in neurology
The safety of ipsilateral high-frequency repetitive transcranial magnetic stimulation in brain tumour patients.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Motor deficits following resection of intrinsic brain tumours impair quality-of-life and survival. Repetitive transcranial magnetic stimulation (rTMS) has shown promise for motor rehabilitation. Only contralesional low-frequency stimulation (CL-LFS) has been tested in this setting. Ipsilesional high-frequency stimulation (IL-HFS), effective in stroke recovery, has not been explored in patients with brain tumours due to several safety concerns, namely: seizure risk, wound healing, and implant heating. Methods: Four patients received IL-HFS and six received standard CL-LFS following resection of motor-eloquent tumours. Patients were eligible for IL-HFS if ipsilateral motor evoked potentials were preserved. Pre- and post-rTMS myotomal strength (MRC) and functional status (AMPAC 6-Click Daily Activity and Mobility) were compared using the Wilcoxon signed-rank test. Adverse events were recorded. Results: All patients demonstrated significant improvements in MRC grade ( Conclusion: IL-HFS rTMS appears to be safe in the early post-operative period following tumour resection. These preliminary findings support further prospective trials evaluating IL-HFS -alone or combined with CL-LFS- to optimise motor recovery in patients with brain tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.